Damora Therapeutics (DMRA) Liabilities and Shareholders Equity (2019 - 2026)

Damora Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $535.4 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 3384.82% year-over-year to $535.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $820.4 million (up 886.41% YoY) and the FY2025 annual result came in at $260.5 million, up 1420.7% from the prior year.
• Liabilities and Shareholders Equity was $535.4 million for Q1 2026 at Damora Therapeutics, up from $260.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $535.4 million in Q1 2026 and bottomed at $10.7 million in Q3 2025.
• A 5-year average of $88.5 million and a median of $50.0 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity plunged 55.18% — and 2026, when it soared 3384.82%.
• Damora Therapeutics' Liabilities and Shareholders Equity stood at $73.2 million in 2022, then tumbled by 47.77% to $38.2 million in 2023, then plunged by 55.18% to $17.1 million in 2024, then soared by 1420.7% to $260.5 million in 2025, then soared by 105.52% to $535.4 million in 2026.
• Business Quant data shows DMRA's Liabilities and Shareholders Equity at $535.4 million in Q1 2026, $260.5 million in Q4 2025, and $10.7 million in Q3 2025.